Tag Archives: Hartaj Singh

Sunesis Pharma (SNSS) Gets a Hold Rating from Oppenheimer

Oppenheimer analyst Hartaj Singh maintained a Hold rating on Sunesis Pharma (SNSS – Research Report) yesterday. The company’s shares closed last Tuesday at $1.35, close to its 52-week low of $1.17. According to TipRanks.com, Singh is a 5-star analyst with

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (NASDAQ: LIFE) and Avita Medical (NASDAQ: RCEL)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on aTyr Pharma (LIFE – Research Report) and Avita Medical (RCEL – Research Report) with bullish sentiments. aTyr Pharma (LIFE) In a report

Analysts Offer Insights on Healthcare Companies: and Catabasis Pharmaceuticals (NASDAQ: CATB)

There’s a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Catabasis Pharmaceuticals (CATB – Research Report) with bullish sentiments. Catabasis Pharmaceuticals (CATB) In a report issued on May 13, Hartaj Singh

Oppenheimer Reaffirms Their Buy Rating on aTyr Pharma (LIFE)

According to TipRanks.com, Singh is a 5-star analyst with an average return of 11.9% and a 46.0% success rate. Singh covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Alexion Pharmaceuticals, and Vertex Pharmaceuticals. The word on The

Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA) and Brainsway (NASDAQ: BWAY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Moderna (MRNA – Research Report) and Brainsway (BWAY – Research Report) with bullish sentiments. Moderna (MRNA) Oppenheimer analyst Hartaj Singh maintained a

Oppenheimer Sticks to Their Hold Rating for Sunesis Pharma (SNSS)

Oppenheimer analyst Hartaj Singh maintained a Hold rating on Sunesis Pharma (SNSS – Research Report) yesterday. The company’s shares closed last Tuesday at $0.33, close to its 52-week low of $0.20. According to TipRanks.com, Singh is a 5-star analyst with